Filing summary
Entity note: The request identifies Pavella Therapeutics, Inc., but the supplied Form 10-K is for Pieris Pharmaceuticals, Inc. This summary covers the filing provided, not Pavella.
Business context and reporting period
Pieris is a clinical-stage biotechnology company developing Anticalin-based therapeutics. This Form 10-K reports the fiscal year ended December 31, 2017, with comparisons to 2016. The principal programs were PRS-343 (HER2/4-1BB immuno-oncology), PRS-060 (inhaled IL-4Rα antagonist for asthma), and PRS-080 (hepcidin antagonist for anemia associated with chronic kidney disease). The company had no approved products and no product-sales revenue.
Financial performance and position
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue | $25.3 million | $5.8 million |
| Research and development expense | $22.3 million | $19.7 million |
| General and administrative expense | $17.6 million | $8.9 million |
| Operating loss | $14.6 million | $22.8 million |
| Net loss | $17.6 million | $22.8 million |
| Net loss per share, basic and diluted | $0.40 | $0.55 |
Revenue was primarily from collaboration and license arrangements. 2017 revenue included $11.3 million of license fees, $12.6 million of milestone payments, and $1.4 million for research and development services. AstraZeneca contributed $19.8 million, Servier $1.9 million, and Roche $3.5 million. No product sales were reported; product gross margin is therefore not applicable.
Operating cash flow was positive $49.8 million in 2017, compared with $14.4 million used in 2016. The 2017 inflow was driven largely by $74.4 million of increased deferred revenue and partnership receipts, rather than profitability. Investing activities used $45.9 million, primarily for investments; financing activities provided $4.1 million, mainly from option and warrant exercises.
At year-end, cash and cash equivalents were $37.9 million and investments were $44.7 million, for total cash, cash equivalents, and investments of $82.6 million. Accounts receivable were $15.5 million. Total liabilities were $92.4 million, including $83.7 million of deferred revenue; stockholders’ equity was $11.5 million. No borrowing balance is shown on the balance sheet. Accumulated deficit was $120.3 million.
Material changes versus 2016
- Revenue increased by $19.4 million, reflecting the new Servier and AstraZeneca collaborations and a $12.6 million AstraZeneca milestone; 2016 included a milestone under the Daiichi collaboration.
- Research and development expense rose $2.6 million, with higher spending on PRS-060, PRS-080, and other research offset by lower PRS-300-series costs.
- General and administrative expense increased $8.7 million, including transaction costs associated with the AstraZeneca, Servier, and Aska arrangements and increased personnel and professional-service costs.
- Net loss narrowed by $5.2 million, despite higher operating expenses, as collaboration revenue grew substantially. Other expense was $2.1 million, mainly from foreign-currency transaction losses, compared with $0.1 million of other income in 2016.
- Cash and investments grew substantially, while deferred revenue increased to $83.7 million, reflecting upfront and other partnership payments not yet recognized as revenue.
Outlook, risks, and unusual items
- Management expected year-end resources, together with the February 2018 public offering and the Seattle Genetics upfront payment, to fund operations and capital expenditures into the middle of 2020. This is a management estimate, not a guarantee.
- In February 2018, Pieris sold 6.325 million shares at $8.00 per share, reporting net proceeds of $47.6 million before approximately $0.3 million of offering expenses. Seattle Genetics paid a $30 million upfront fee under a new collaboration; the agreement also provides for up to $1.2 billion in success-based payments and tiered royalties, subject to development and commercial outcomes.
- Clinical progress remained early-stage: PRS-343 and PRS-060 entered Phase I in 2017; PRS-080 began a Phase IIa study in dialysis-dependent CKD patients. Management expected PRS-080 dosing completion in 2018 and planned a PRS-060 proof-of-mechanism study in the second half of 2018. These are forward-looking plans.
- The company reported a material weakness in internal control over financial reporting as of December 31, 2017, involving the financial close process and errors in expense classification and foreign-currency remeasurement. The errors were corrected before issuance, and management described a remediation plan; management nevertheless concluded controls were not effective.
- Key risks include continued losses and dependence on additional financing; clinical, regulatory, and commercialization uncertainty; reliance on collaborators and third-party manufacturers; intense competition; foreign-exchange exposure; and dependence on patent and license rights. A Daiichi Sankyo program termination in March 2018 returned the CGRP migraine program to Pieris and eliminated future milestones under that program.
- The filing identifies no material legal proceedings and no off-balance-sheet arrangements. It reports no cash dividends and no product approvals.
Important facts for investors to verify
- Confirm that Pieris Pharmaceuticals, Inc.—not Pavella Therapeutics, Inc.—is the intended issuer.
- Review the audited financial statements and notes for the composition and liquidity of investments, deferred revenue recognition, and partnership-related receivables.
- Assess the basis for management’s mid-2020 cash runway estimate, including clinical spending, collaboration funding, and the effect of future milestones or partner decisions.
- Track clinical-trial enrollment, safety, and results for PRS-343, PRS-060, and PRS-080, and distinguish planned milestones from achieved results.
- Monitor remediation of the disclosed material weakness and any subsequent changes in financial-reporting controls.
- Review dilution and share overhang, including the February 2018 offering, outstanding options and warrants, and resale-eligible shares.